Docoh
Loading...

Thu. 8 Apr 2021, 1:00pm ETBenzinga
In: News, Price Target, Analyst Ratings
SVB Leerink analyst Mani Foroohar maintains Dicerna Pharmaceuticals (NASDAQ:DRNA) with a Outperform and lowers the price target from $45 to $44.